Buy Online Triptorelin – Triptorelin Peptide Research
Triptorelin is a peptide made up of ten amino acids in its sequence. The peptide is categorized under gonadotrophin releasing hormone agonists and it is known by several other names such as decapeptyl, gonapeptyl and diphereline.
Triptorelin has a molecular formula of C64H82N18O13, and a molecular mass of 1311.5 Daltons. Studies indicated that the peptide has three important tasks in a biological system. These include:
- Stimulating the secretion of luteinizing hormone – when the triptorelin peptide is present in a biological system, it stimulates the secretion of growth hormone. The peptide released from the anterior lobe of the pituitary gland is essential for growth, sex, metabolism and development, among other essential functions.
- Reducing the secretion of luteinizing hormone – when the triptorelin peptide is administered to a biological system, it reduces the secretion of luteinizing hormone. Recent studies indicated that the peptide is essential for controlling and regulating estrogen and testosterone in females and males respectively. This secretion is very crucial because it regulates the reproduction process.
- Reducing the production of follicle stimulating hormone –triptorelin has the ability to induce a drop in the levels of follicle stimulating hormone. The expression is essential in controlling growth and development, especially during puberty and maturation.
Read More »
Triptorelin is a crucial peptide which has the ability to alleviate various conditions that occur in the system, and there is research to back the data. Recent studies indicated that when the peptide is administered, it reduces secretion of certain hormones and increases the production of growth hormone. The main benefit of the peptide is that it helps to prevent and reduce the development of tumorous cells. This is one of the areas that have gained huge interest among many scholars and researchers.
There are certain cancer forms that are linked to the secretion of the luteinizing hormone. The cancers include prostate and breast cancer. When the levels of estrogen and testosterone are increased or reduced in a medium, the amount of these hormones largely affects the growth and multiplication of cells. Triptorelin has the ability to lower the production of luteinizing hormone and there are postulated benefits that the peptide could be beneficial to alleviating certain cancers.
One area of study is the use of the triptorelin peptide to treat cancers related to low levels of calcium in the system. The luteinizing hormone is important for reducing the production of estrogen. The regulation of estrogen production could reduce the amount of the cancerous cells in the system. The studies further showed that the peptide has a positive feedback mechanism in alleviating numerous conditions such as endometriosis and uterine fibroids. Since the triptorelin peptide is crucial in regulating levels of follicle stimulating hormone, it can reduce the occurrence of precocious puberty. Studies done on animal suggest indicated that administration of the peptide results in insomnia, muscle pain, shivering and other general discomfort. However, these effects often vary with the dosage administered to the test organism.
Triptorelin and Prostate Cancer
Triptorelin is an essential peptide for accentuating the alleviation of adverse effects of metastatic prostate cancer . The peptide was administered to research mice and it showed a reduction in the number of metastatic cells in the prostate of the cancerous mice. The neoadjuvant treatment prior to radiotherapy with the administration of the peptide. Research focused on the administration of the triptorelin peptide in turns and this resulted in a reduction of metastatic cells in the system with the injection administered once every three months.
When the peptide is administered like any other gonadotrophin releasing hormone, it causes transient increases in levels of testosterone in the serum. Consequently, in some isolated cases, the transient worsening of prostate cancer could develop in the first weeks of treatment. The administration of the triptorelin peptide to mice increased the levels of testosterone and this treatment should be countered with the administration of anti-androgen. Administration of anti-androgen is very crucial because it reduces clinical symptoms of the peptide.
There are a few test animal subjects that experienced tumor flare and this contributed to cancer-related pain or metastatic pain. Just like other gonadotrophin releasing hormones, urethral obstruction and spinal cord compression occurred. In such a case, if spinal cord compression occurs, then the complication should be alleviated using immediate orchidectomy. Careful monitoring of test subjects should be done to avoid cases of vertebral metastasis.
This is essential especially in the first few weeks. This is the time when the rates of spinal cord compression are high and urinary tract obstruction could occur. In a situation where surgical castration is included, then the administration of the triptorelin peptide does not affect the level of testosterone in the system. Long-term deprivation of androgen through administration of the gonadotrophin releasing, a hormone or by bilateral orchidectomy, could increase the risk of bone loss and this could lead to increase chances of bone fracture and osteoporosis.
Research showed that the administration of triptorelin resulted in an increase in the production of estrogen and other androgenic hormone. However, you should conduct a benefit-risk ratio to assess the situation if you really need to use the technique or find an alternative. According to previous studies, it has been documented that when triptorelin is administered, it could bring metabolic changes and this may increase the risk of cardiovascular diseases. In most cases, the researcher should identify the causative agents of an increase in the level of hormonal production.
For the test subjects that have a higher risk of cardiovascular diseases, then you can conduct a research before inducing the triptorelin peptide. Moreover, blood pressure, cholesterol and glucose levels should be closely monitored before treatment begins. Cardiovascular mortality is increased in cases where parameters are not monitored closely. This could bring changes in the overall functionality of triptorelin.
When the peptide is administered in therapeutic doses, it resulted in the suppression of the pituitary-gonadal system. This is altered in the short term. However, when dosage increases with time, it resulted in a rapid increase in the production of various hormones.
Research done on male mice indicated that when the triptorelin peptide is administered, it leads to the release of pituitary gonadotrophin with a transient increase in the level of testosterone in the system. A prolonged administration of the peptide could lead to a suppression of gonadotrophin as well as reduction of estradiol or testosterone in the system. The efficacy and the safety of the triptorelin peptide are not ascertained, therefore, it is only used for scientific research purposes and human consumption is prohibited. The administration of the peptide on male mice caused a significant reduction in size and cessation of tumor cell multiplication.
Triptorelin and Endometriosis
As indicated earlier, the administration of triptorelin should occur once every three months. The treatment should be initiated in the first five days and it depends on the initial severity of endometriosis. Changes observed in clinical features which include anatomical and functional features, must be put into consideration when conducting the research. The maximum period of study should be within 2 injections or six months.
The main concern of limiting the study to six months is because subsequent administration of the triptorelin peptide causes changes in bone density and this could lead to bone fractures. Studies revealed that the use of the peptide could result in a reduction of bone mineral density by up to 1% per month and every 10% decrease in bone mineral density increases the risk of bone fracture by 2-3 times. It is imperative to note that studies conducted on female mice showed that the recovery of bone loss occurs after the therapy has ceased.
Recommended dosage depends on the objectives of the study and sensitivity of the triptorelin peptide to certain conditions. However, it is imperative that you begin with a low dosage as you move to higher dosage because this will help acclimatize the test subject to the peptide administration. Studies done on female mice showed that ovarian function resumed after five months from the last injections. The use of any gonadotrophin releasing hormone usually results in a reduction in bone mineral density.
Research on male mice showed that the use of bisphosphonate and a combination of gonadotrophin releasing hormone resulted in bone mineral loss. However, no specific data is available to clearly pinpoint if the osteoporosis present is directly linked to triptorelin or the prevailing conditions. Research showed that triptorelin increases the likelihood of bone mineral density loss and it is necessary to increase bone building supplements during the study to reduce brittle bones or breaking of bones.
The research and treatment using triptorelin is based on an individual test animal and it should not be replicated on another organism. Consideration should be taken to account for bone mineral density loss and that the peptide will induce the desired reaction. However, it is imperative to note that the treatment of gonadotrophin releasing hormone agonist may reveal the presence of a previous condition .
In such a case, the test subject shows various symptoms such as visual impairment, ophthalmoplegia and nausea, among other features. The administration of the triptorelin peptide to the test organism has shown an increase in the production of various essential compounds in the biological system. The test organisms should be carefully monitored for any changes in the functionality of the peptide and how to use it effectively.
Triptorelin and Precocious Puberty
The research on precocious puberty is done through the administration of the triptorelin peptide once every three months. The research was conducted on young mice as their cell replication rates were at their highest. It is important to understand that administration of triptorelin should be closely monitored and indicated contraindications should be written to see if there is any considerable change in the parameters.
Treatment of the peptide should be stopped at some point when it is considered that triptorelin has brought about desired effects. There is limited data to pinpoint the efficacy of the peptide in accentuating the decrease in production of estrogen and luteinizing hormone in the biological system. The administration of the triptorelin peptide on the mice with tumor cells in the brain showed a positive feedback and it is imperative that you weigh the risks and benefits of administering the peptide to test subjects.
Research on female mice showed that when the triptorelin peptide is administered, the treatment induced estrogen withdrawal and this may cause bleeding ranging from mild to moderate intensity. This is pseudo-precocious puberty or what is commonly called adrenal hyperplasia or gonadal hyperplasia. Bone mineral density will decrease with the administration of gonadotrophin releasing hormone. However, after cessation of administration of triptorelin, the mass accrued is seen. The slipped capital femoral epiphysis is seen when application of the peptide and there is a postulated theory that low concentration during the treatment with the triptorelin peptide could weaken the epiphyseal plate. There are drugs which increase levels of prolactin in the system. These should not be administered alongside triptorelin because the interaction could result in adverse side effects.
Co-administration of triptorelin alongside other drugs has shown to affect pituitary secretion of the gonadotrophin. Caution should be exercised when or before administering the peptide. Androgen deprivation treatment may prolong the QT interval and the use of other products alongside the peptide could result in cellular damage and hemorrhage in some cases. In addition, the use of the peptide in pregnant mice showed adverse side effects.
Therefore, the peptide should not be used in pregnant test species. Side effects include fetal abnormality or abortion. You should examine the test organism before injecting the peptide. During surveillance, the peptide might have teratogenic effects and it should be investigated further for functionality in accentuating the release of luteinizing and follicle stimulating hormone. According to the pharmacokinetics of drugs, efficacy and potency of the triptorelin peptide largely depend on its overall functionality and amino acid arrangement.